Trading Halted Optimer Pharmaceuticals Stock Due to FDA Advisory Committee Reviewing Fidaxomicin Data in Clostridium difficile Infection

Optimer Pharmaceuticals, Inc. OPTR announced today that NASDAQ has halted trading of the Company's common stock this morning. The Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. Food and Drug Administration (FDA) is scheduled to meet today to review and discuss Optimer's New Drug Application (NDA) for fidaxomicin for the treatment of Clostridium difficile infection.